Review articlePublished 2016

Focusing New Ataxia Telangiectasia Therapeutic Approaches

Authors: Luciana Chessa, Roberto Micheli, Anna Molinaro

Journal of Rare Disorders: Diagnosis & Therapy

Volume 2 · Issue 2 · Pages 12

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Ataxia Telangiectasia (AT) is a rare worldwide disease inherited as autosomal recessive with a poor prognosis in its classical form. It is characterized by neurological impairment (progressive cerebellar ataxia, axonal peripheral neuropathy, oculomotor apraxia, and movement disorders such as dystonia, choreoathetosis, myoclonus, tremor, Parkinsonism), telangiectasias, recurrent sino pulmonary infections, proneness to cancer, increased alpha-fetoprotein and decreased IgA levels and radio hypersensitivity. AT is caused by biallelic mutations in ATM gene, which plays a pivotal role in the control of cell cycle and in the response to DNA double strand break damage and chromatin changes. The management of patients, as well as prognosis, depends on the severity of the phenotype; only symptomatic therapies are by now available. Here we discuss the classical and the new therapeutic approaches in the light of the most recent reports in the literature.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Rare Disorders: Diagnosis & Therapy
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Luciana Chessa”
  • BylineArticles whose byline prints “Roberto Micheli”
  • BylineArticles whose byline prints “Anna Molinaro”